- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Mi | Caribou to halt CAR-T work, lay off staff amid 'challenging' funding climate | ||
| Mi | Halozyme prevails in patent fight with Merck; Enliven readies anticipated leukemia trial | ||
| Mi | A Takeda spinout builds case for its Parkinson's drug | ||
| Di | Forbion, a prominent biotech investor, raises $2.6B for a pair of venture funds | ||
| Di | ArriVent collapses on disappointing lung cancer data | ||
| Di | Dual-acting drug from AbbVie, Genmab scores in frontline lymphoma trial | ||
| Di | [Podcast] (Season 2) The Progress Profile: Alzheimer's Research in Focus | ||
| Di | The top biopharma conferences in 2027 | ||
| Di | GE HealthCare to acquire Sofie Biosciences for $945M | ||
| Mo | Shionogi pays $2B to acquire a rare disease startup | ||
| Mo | Optogenics researchers win a Nobel Prize; Roche bets on Alector brain drug | ||
| Mo | Vaxcyte skyrockets on 'near best-case' pneumococcal vaccine data | ||
| Mo | Precision for All: Closing the gap between innovation and impact | ||
| Mo | How AI is transforming biopharma manufacturing facilities of the future | ||
| Fr | This week in charts: Kodiak's big comeback and Hengrui's dealmaking | ||
| 01.10. | 3 takeaways from a European obesity scientific meeting | ||
| 01.10. | Sanofi, Regeneron broaden alliance to find their next Dupixent | ||
| 01.10. | HHS kicks off new programs to speed clinical trials as Chinese competition looms | ||
| 01.10. | 5 FDA decisions to watch in the fourth quarter of 2026 | ||
| 30.09. | Bristol Myers trial revisions shake confidence in new class of fibrosis drugs | ||
| 30.09. | FDA starts review of Roche's multiple sclerosis pill | ||
| 30.09. | PhRMA names next CEO; Pierre Fabre takes third swing at Ebvallo approval | ||
| 29.09. | Beam sues 2 biotechs, alleging theft of base editing trade secrets | ||
| 29.09. | Novo to pay Hengrui up to $2.6B for a once-weekly obesity pill | ||
| 29.09. | UniQure tumbles with latest data for Huntington's gene therapy |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.